PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2011
CASE
AUTH/2454/11/11 Celgene

AUTH/2454/11/11: Pharmacist v Celgene β€” advisory board honoraria alleged as disguised promotion (No breach)

A hospital pharmacist alleged Celgene’s Vidaza advisory boards (incl. Β£600 honorarium) were disguised promotion/inducement around SMC timing. PMCPA found legitimate consultancy need,…

2018
CASE
AUTH/3071/9/18 Novo Nordisk

AUTH/3071/9/18: Director v Novo Nordisk β€” Clinical trial disclosure (No breach)

BMJ analysis suggested Novo Nordisk had 1 β€œdue” EUCTR trial without posted results (98.1% compliance). Company said the trial was withdrawn before…

2018
CASE
AUTH/3076/9/18 AstraZeneca

AUTH/3076/9/18: Director v AstraZeneca – Clinical trial disclosure (outwith scope; no breach)

PMCPA case AUTH/3076/9/18 (Director v AstraZeneca) about clinical trial disclosure. The matter was ruled outwith the scope of the ABPI Code (2016).…

2011
CASE
AUTH/2414/6/11 AstraZeneca ⭐ Case of the Week

AUTH/2414/6/11: Hospital Doctor v AstraZeneca – β€œTraining day research invitation” for rep capability workshop (No breach on appeal)

A doctor challenged a third‑party invitation to a paid β€œtraining day research” workshop for rep mock consultations. Panel initially found disguised promotion,…

2012
CASE
AUTH/2510/6/12 ProStrakan

AUTH/2510/6/12: Anonymous v ProStrakan (Abstral) – alleged misleading titration advice (No breach)

Anonymous physician alleged a ProStrakan rep gave an incorrect day-by-day Abstral titration schedule. Panel found the complaint unproven on the balance of…

2012
CASE
AUTH/2479/2/12 AstraZeneca

Novo Nordisk v Bristol-Myers Squibb & AstraZeneca: symposium on unlicensed dapagliflozin found not promotional (AUTH/2479/2/12, AUTH/2480/2/12)

Novo Nordisk alleged a PCDS satellite symposium promoted unlicensed dapagliflozin and that sales reps attended. The Panel found the complaint not proven…

2011
CASE
AUTH/2461/12/11 AstraZeneca

AUTH/2461/12/11: Anonymous v AstraZeneca β€” complaint about representative conduct (no breach)

Anonymous practice manager alleged rude/intimidating rep behaviour, diary giveaways and discussion of an unlicensed diabetes medicine. Panel found no supporting evidence and…

2012
CASE
AUTH/2527/8/12 Shire Pharmaceuticals

AUTH/2527/8/12: Anonymous v Shire β€” alleged pre-licence promotion via MSLs and advisory boards (No breach)

Anonymous HCP alleged Shire MSLs created β€œnoise” about unlicensed Vyvanse (LDX), set targets and encouraged named-patient use; also raised repeated advisory boards.…

2012
CASE
AUTH/2569/12/12 Novo Nordisk ⭐ Case of the Week

Merck Sharp & Dohme v Novo Nordisk: Victoza detail aid and misleading composite endpoint presentation (AUTH/2569/12/12)

MSD challenged a Victoza detail aid using a composite endpoint. Panel found the prominent red β€œHbA1c<7% + weight loss + no hypos”…

2012
CASE
AUTH/2539/11/12 Vifor Pharma

AUTH/2539/11/12: Pharmacosmos v Vifor Pharma β€” exclusivity clauses in HCP consultancy contracts (No breach)

Pharmacosmos alleged Vifor used exclusivity/non-compete clauses in HCP consultancy contracts, potentially creating improper β€˜retainer’ arrangements. The Panel found Pharmacosmos hadn’t proven a…

2013
CASE
AUTH/2588/3/13 Novartis Pharmaceuticals UK

Novartis breach: Seebri Breezhaler evidence review misleading on COPD mortality and exacerbations (AUTH/2588/3/13)

A formulary-pack β€œEvidence Review” for Seebri Breezhaler claimed 180‑day mortality after COPD exacerbation was 33% and implied reducing exacerbations reduces mortality. PMCPA…

2012
CASE
Novartis Pharmaceuticals UK

Novartis voluntary admission: three Lucentis ads appeared in one journal issue (Clause 6.3)

Novartis admitted Ophthalmology Times Europe (Sept 2013) carried Lucentis advertising on three pages after a publisher duplicated the back cover via a…

2013
CASE
AUTH/2612/6/13 Gedeon Richter

Gedeon Richter: third-party event tweets held to promote a POM to the public (AUTH/2612/6/13)

An events agency tweeted about a Gedeon Richter meeting, naming ulipristal acetate and use in fibroid patients. PMCPA ruled this advertised a…

2013
CASE
AUTH/2631/8/13 Bayer ⭐ Case of the Week

Anonymous v Bayer: BJMA β€˜Annual Scientific Meeting’ sponsorship ruled mainly social, not primarily educational (AUTH/2631/8/13)

Bayer sponsored a BJMA UK meeting in Bolton (July 2013) with a stand and speaker. Panel found the event was mainly social/cultural…

2013
CASE
AUTH/2646/10/13 Merck Sharp & Dohme

AUTH/2646/10/13: MSD breached ABPI Code over unclear sponsorship disclosure at public health screening event (Health Mela)

Anonymous HCP alleged MSD reps hovered near public screening and confidentiality was poor. Panel found no proof reps engaged with screening, but…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training